icad Inc ICAD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
iAccess Alpha's Buyside Best Ideas Virtual Fall Conference September 24-25, 2024
-
iCAD to Participate in the iAccess Alpha Buyside Best Ideas Fall Conference 2024
-
iCAD Reports Financial Results for Second Quarter Ended June 30, 2024
-
iCAD to Report Second Quarter 2024 Financial Results on August 13, 2024
-
iCAD and Windsong Radiology Announce Strategic Commercial Agreement to Implement AI-Powered Mammography
Trading Information
- Previous Close Price
- $1.55
- Day Range
- $1.56–1.65
- 52-Week Range
- $1.18–2.65
- Bid/Ask
- $1.46 / $1.70
- Market Cap
- $42.56 Mil
- Volume/Avg
- 116,128 / 163,804
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.16
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 69
- Website
- https://www.icadmed.com
Valuation
|
Metric
|
ICAD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.32 |
Price/Sales | 2.16 |
Price/Cash Flow | — |
Price/Earnings
ICAD
Financial Strength
|
Metric
|
ICAD
|
|---|---|
Quick Ratio | 3.92 |
Current Ratio | 4.24 |
Interest Coverage | −379.21 |
Quick Ratio
ICAD
Profitability
|
Metric
|
ICAD
|
|---|---|
Return on Assets (Normalized) | −11.13% |
Return on Equity (Normalized) | −14.89% |
Return on Invested Capital (Normalized) | −16.35% |
Return on Assets
ICAD
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Fmfvzhqx | Dhdfr | $195.9 Bil | |||
| Stryker Corp
SYK
| Smsbkmtyp | Bhxq | $137.0 Bil | |||
| Boston Scientific Corp
BSX
| Tqbrdnyk | Mjdxh | $123.0 Bil | |||
| Medtronic PLC
MDT
| Rqxcxnyf | Khkkcf | $114.7 Bil | |||
| Edwards Lifesciences Corp
EW
| Jcmxwtnj | Hwplps | $39.4 Bil | |||
| Koninklijke Philips NV ADR
PHG
| Rcz | Qyp | $29.1 Bil | |||
| DexCom Inc
DXCM
| Vzbkrgnbnd | Ggkl | $26.7 Bil | |||
| Steris PLC
STE
| Xmvtgzvw | Blsqm | $23.3 Bil | |||
| Zimmer Biomet Holdings Inc
ZBH
| Rcshyljzmr | Sxhcv | $21.7 Bil | |||
| Insulet Corp
PODD
| Pmrsszhcbz | Rrdmz | $16.7 Bil |
United States